WHO 2020/9/22まとめ

WHO　2020/11/12まとめ

赤字は中国企業　　IM＝Intramuscular 筋肉注射　ID＝intradermal　皮内注射

*AstraZenecaワクチンは1回接種となっているが、治験は2回

Developer/manufacturer	Platform	Type	doses	Timing	Route	Phase				承認
Developer/manufacturer	Platform	Type	doses	Timing	Route	1	1/2	2	3	承認
University of Oxford/AstraZeneca	Non-Replicating Viral Vector	ChAdOx1-S	1*		IM		〇	〇	〇	UK 2020/12/30 EU 2021/1/29　③
CanSinoBiological Inc./Beijing Institute of Biotechnology	Non-Replicating Viral Vector	Adenovirus Type 5 Vector	1		IM	〇		〇	〇
Gamaleya Research Institute（ロシア）	Non-Replicating Viral Vector	Adeno-based	2	0, 21 days	IM		〇	〇	〇	Sputnik V ロシア　2020/8
Vektor (State Research Center for Virology and Biotechnology) ロシア										EpiVacCorona ロシア　2020/10
Janssen Pharmaceutical (J&J)	Non-Replicating Viral Vector	Ad26COVS1	1		IM		〇		〇	FDA 2021/2/27 WHO 2021/3/12 EU 2021/3/11　④
Sinovac（中国）	Inactivated	Inactivated	2	0, 14 days	IM		〇		〇	中国 2021/2/6
Wuhan Institute of Biological Products/Sinopharm	Inactivated	Inactivated	2	0,14 or 0,21 days	IM		〇	〇	〇
Beijing Institute of Biological Products/Sinopharm	Inactivated	Inactivated	2	0,14 or 0,21 days	IM		〇		〇	中国 2020/12/31
Bharat Biotech　（インド）	Inactivated	Whole-Virion Inactivated	2	0, 14 days	IM		〇		〇	Covaxin インド 2021/1/3
Moderna/NIAID（米国立アレルギー感染症研究所）	RNA	LNP-encapsulated mRNA	2	0, 28 days	IM	〇		〇	〇	FDA 2020/12/17 EU 2021/1/6　②
BioNTech（独）/Fosun Pharma（上海復星医薬）/Pfizer 　〔前2社が提携〕	RNA	3 LNP-mRNAs	2	0, 28days	IM	〇	〇		〇	UK 2020/12/2 FDA 2020/12/11 EU 2020/12/21 ① WHO 2020/12/31
Novavax（米）	Protein Subunit	Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M	2	0, 21 days	IM		〇	〇	〇	EU 2021/12/20 ⑤
Beijing Wantai Biological Pharmacy/ Xiamen University	Replicating Viral Vector	Intranasal flu-based-RBD	1		IM	〇		〇
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences	Protein Subunit	Adjuvanted recombinant protein (RBD-Dimer)	2 or 3	0,28 or 0,28,56 days	IM	〇	〇	〇
Curevac（独）	RNA	mRNA	2	0, 28 days	IM	〇		〇
Institute of Medical Biology, Chinese Academy of Medical Sciences	Inactivated	Inactivated	2	0, 28 days	IM	〇	〇
Research Institute fo Bological Safety Problems, Rep. of Kazakhstan	Inactivated	Inactivated	2	0, 21 days	IM		〇
Beijing Minhai Biotechnology	Inactivated	Inactivated	2		IM	〇	〇
Inovio Pharmaceuticals(米）/ International Vaccine Institute	DNA	DNA plasmid vaccine with electroporation	2	0, 28 days	ID		〇
Osaka University/ AnGes/ Takara Bio	DNA	DNA plasmid vaccine + Adjuvant	2	0, 14 days	IM		〇
Cadila Healthcare (Zydus Cadila：インド）	DNA	DNA plasmid vaccine (ZyCoV-D)	3	0, 28, 56 days	ID		〇
Genexine Consortium(韓国）	DNA	DNA Vaccine (GX-19)	2	0, 28 days	IM		〇
Kentucky Bioprocessing（米）	Protein Subunit	RBD-based	2	0, 21 days	IM		〇
Sanofi Pasteur/GSK	Protein Subunit	S Protein (baculovirus production)	2	0, 21 days	IM		〇
Biological E Ltd　(インド）	Protein Subunit	Adjuvanted protein subunit (PBD)	2	0, 28days	IM		〇
Israel Institute for Biological Research	Replicating Viral Vector	VSV-S	1		IM		〇
Arcturus（米）/Duke-NUS（シンガポール）	RNA	mRNA			IM		〇
SpyBiotech/Serum Institute of India	VLP	RBD-HBsAg VLPs	2	0, 28days	IM		〇
Symvivo　カナダ	DNA	bacTRL-Spike	1		oral	〇
ImmunityBio, Inc & Nantkwest Inc　米	Non-Replicating Viral Vector	hAd5 S+N 2nd Generation Human Adenovirus Type 5 Vector (hAd5) Spike(S) + Nucleocapsid (N)	2	0, 21days	SC	〇
ReiThera（伊）/LEUKOCARE（独）/Univercells（ベルギー）	Non-Replicating Viral Vector	Replication defective Simian Adenovirus (GARs) encoding S	1		IM	〇
CanSino Biological Inc/Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China	Non-Replicating Viral Vector	Ad5-nCoV	2	0, 28days	IM/mucosal	〇
Vaxart　米	Non-Replicating Viral Vector	Ad5 adjuvanted Oral Vaccine platform	2	0, 28days	oral	〇
Ludwig-Maximiliants- Univ. of Munich	Non-Replicating Viral Vector	MVA-SARS-2-5	2	0, 28days	IM	〇
Clover Biopharmaceuticals Inc./GSK/Dynavax	Protein Subunit	Native like Trimeric subunit Spike Protein vaccine	2	0, 21 days	IM	〇
Vaxine Pty Ltd（豪）/Medytox（韓）	Protein Subunit	Recombinant spike protein with Advax™ adjuvant	1		IM	〇
University of Queensland/CSL（豪）/Seqirus（英）	Protein Subunit	Molecular clamp stabilized Spike protein with MF59 adjuvant	2	0, 28 days	IM	〇
Medigen Vaccine Biologics（台湾）/NIAID/Dynavax	Protein Subunit	S-2P protein + CpG 1018	2	0, 28 days	IM	〇
Instituto Finlay de Vacunas, Cuba	Protein Subunit	rPBD produced in CHO-cell chemically conjugate to tetanus toxoid	2	0, 28 days	IM	〇
Instituto Finlay de Vacunas, Cuba	Protein Subunit	PBD + Adjutant	2	0, 28 days	IM	〇
FBRI SRC VB Vector, Rospotrebnadzor, Koltsovo　　　Russia	Protein Subunit	Reptide	2	0, 21days	IM	〇
West China Hospital, Sichuan University	Protein Subunit	PBD (baculovirus production expressed in Sf9 cells)	2	0, 28 days	IM	〇
University Hospital Tuebingen　独	Protein Subunit	SARS-CoV-2 HLA-DR peptides	1		SC	〇
COVAXX (United Biomedical )	Protein Subunit	S1-RBD-protein	2	0, 28 days	IM	〇
Merck Sharp & Dohme/ IAVL	Replicating Viral Vector	Replication-competent VSV delivering the SARS-CoV-2 Spike	1		IM	〇
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme	Replicating Viral Vector	Measles-vector based	1 or 2	0, 28 days	IM	〇
Imperial College London	RNA	LNP-nCoVsaRNA	2		IM	〇
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech（云南沃森生物）	RNA	mRNA	2	0, 14 or 0, 28 days	IM	〇
Medicago（カナダ　田辺三菱製薬）	VLP	Plant-derived VLP adjuvanted with GSK or Dynavax adjs.	2	0, 21 days	IM	〇

1995/3	遺伝子治療関連技術開発を目的とした、国家研究プロジェクトが開始され、医薬品機構及び製薬会社7社が出資し、㈱ディナベック研究所　設立
2003/9	経営陣と製薬会社4社（協和発酵工業、三共、久光製薬、山之内製薬）が出資、上記から営業譲渡を受け、ディナベック㈱を設立
2006/3	エーザイと「センダイウイルスベクターを用いたアルツハイマー病用ワクチンの開発」に関する研究協力契約を締結
2013/10	㈱アイロムホールディングスの子会社に
2015/4	㈱IDファーマに改称